Steris plc stock (IE00BFY8C754): Shares up 1.41% to $230.46 on Jul 25

Steris plc (NYSE:STE) stock rose 1.41% to $230.46 on July 25, 2025, amid positive signals in the medical equipment sector. The company holds a Moderate Buy consensus rating with 28.32% upside potential.

Steris plc stock gained 1.41% on the last trading day, Friday, July 25, 2025, closing at $230.46 after rising from $227.25, according to stockinvest.us as of Jul 2025. The NYSE-listed medical device firm shows accumulated volume support at $225.58, signaling potential buying opportunities. Analysts maintain a Moderate Buy consensus with a 2.71 rating score and predicted 28.32% upside, per MarketBeat as of 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Steris plc
• Sector/industry: Medical Devices
• Headquarters/country: Ireland
• Core markets: US, Europe
• Key revenue drivers: Infection prevention, sterilization
• Home exchange/listing venue: NYSE (STE)
• Trading currency: USD

Steris plc: core business model

Steris plc provides infection prevention and other surgical products and services worldwide. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. Healthcare products include sterilizer systems, washing systems, and surgical tables used in hospitals and clinics. This focus positions Steris plc as a key player in healthcare infrastructure, particularly relevant for US investors given the sector's growth amid rising healthcare spending.

Main revenue and product drivers for Steris plc

Steris plc generates revenue primarily from infection control solutions, including high-level disinfectants and sterilization equipment. The Healthcare segment drives significant sales through consumables and capital equipment. Recent market projections highlight the infection control market reaching $503.7 billion by 2035, with Steris plc listed among major players alongside 3M and Getinge AB, according to GlobeNewswire as of 05/14/2026. US market exposure remains a core driver due to demand in hospitals.

Industry trends and competitive position

The medical devices industry sees steady demand from aging populations and post-pandemic hygiene focus. Steris plc competes with Boston Scientific (BSX) and Edwards Lifesciences (EW) in med instruments, maintaining a market cap of about $21.53 billion, per MarketBeat data. Its Moderate Buy rating outperforms the broader market's Hold consensus, underscoring stability for US portfolios.

Why Steris plc matters for US investors

Listed on NYSE, Steris plc offers US investors access to a global leader in sterilization with substantial US revenue exposure. The stock's medium risk profile, average daily movements, and positive volume support at key levels appeal to those tracking healthcare trends amid economic recovery.

Conclusion

Steris plc demonstrates resilience with a recent 1.41% price gain to $230.46 on July 25, 2025, supported by analyst optimism and sector tailwinds. The company's position in infection control amid market growth projections offers visibility, though investors monitor volume and support levels. Balanced exposure to US healthcare makes it noteworthy for diversified portfolios.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.